An increased risk of local-regional recurrence in stage 1 non–small cell lung cancer (NSCLC) was found in individuals who needed a percutaneous transthoracic needle biopsy (PTNB) prior to their ...
Adjuvant treatment with Alecensa (alectinib) elicited a 4-year overall survival (OS) rate of 98.4% for patients with resected ALK-positive early stage non–small cell lung cancer (NSCLC) according to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback